ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals granted 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees as employment inducement grants on September 1, 2026, under its 2022 Inducement Equity Incentive Plan as permitted by Nasdaq Rule 5635(c)(4). Vesting is standard: options vest 25% on the one-year anniversary with 1/36 of the remainder vesting monthly thereafter, and RSUs vest in thirds on the first three anniversaries; the option exercise price equals the closing price on the grant date.
Key figures
- Grant date
- 2026-09-01
- Recipients
- 2
- Rsus granted
- 6400
- Options granted
- 39200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.